Verteporfin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Verteporfin
Verteporfin.svg
Clinical data
Trade namesVisudyne
AHFS/Drugs.comMonograph
MedlinePlusa607060
License data
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Identifiers
  • 3-[(23S,24R)-14-ethenyl-5-(3-methoxy-3-oxopropyl)-22,23-bis(methoxycarbonyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC41H42N4O8
Molar mass718.807 g·mol−1
3D model (JSmol)
  • COC(=O)CCC=1C(C)=C2C=C6N=C(C=C4NC(=CC3=NC(=CC=1N2)C(CCC(O)=O)=C3C)C(C=C)=C4C)C5=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@]56C
  • InChI=1S/C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h9-10,13,16-19,38,43,45H,1,11-12,14-15H2,2-8H3,(H,46,47)/b31-16-,33-18-,34-17-,35-19-/t38-,41+/m0/s1 checkY
  • Key:ZCQHFRFEJXRZDF-YWANUUMDSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Verteporfin (trade name Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 689 nm[1] in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.[2][3]

Verteporfin is also used off-label for the treatment of central serous retinopathy.[4]

Administration[edit]

Verteporfin is given intravenously, 15 minutes before laser treatment.[2]

Contraindications[edit]

Porphyria.[2]

Side effects[edit]

Most common side effects are blurred vision, headache, and local effects at the injection site. Also, photosensitivity; it is strictly advised to avoid exposure to sunlight and unscreened lighting until 48 hours after verteporfin administration.[2]

Interactions[edit]

Verteporfin is known to interact with the herbal remedy feverfew (Tanacetum parthenium), the latter of which seems to act as an antagonist to verteporfin for unknown reasons. Taking the two substances simultaneously is inadvisable.[5]

Verteporfin does not appear to be metabolized by Cytochrome P450 enzymes, therefore not affecting Cytochrome P450 metabolism of other drugs.[6]

Potential against scarring[edit]

Verteporfin is mentioned as a marketed drug having effects sought during current research into elimination of scarring in the skin tissue healing process among humans.[7]

References[edit]

  1. ^ "Visudyne package insert" (PDF).
  2. ^ a b c d Verteporfin Monograph
  3. ^ Scott LJ, Goa KL (February 2000). "Verteporfin". Drugs & Aging. 16 (2): 139–46, discussion 147-8. doi:10.2165/00002512-200016020-00005. PMID 10755329.
  4. ^ Karim SP, Adelman RA (2013). "Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy". Clinical Ophthalmology. 7: 1867–75. doi:10.2147/OPTH.S32177. PMC 3788817. PMID 24092965.
  5. ^ "Feverfew and Verteporfin Interactions". Drugs.com. Retrieved 14 April 2015.
  6. ^ "Visudyne (verteporfin for injection) prescribing information" (PDF). FDA. FDA. Retrieved 12 April 2021.
  7. ^ Molteni, Megan, In mouse experiments, scientists unlock the key to scar-free skin healing, STAT News, April 22, 2021

External links[edit]